Literature DB >> 33211209

The significance of myositis autoantibodies in idiopathic inflammatory myopathy concomitant with interstitial lung disease.

Wen-Chih Lin1, Po-Yu Lin2, Hung-Ling Huang3, Meng-Yu Weng4, Yuan-Ting Sun5,6.   

Abstract

AIM: This study identified factors associated with interstitial lung disease (ILD) in patients with idiopathic inflammatory myopathy (IIM) based on the latest classification and recent advances in autoantibody serology.
METHODS: We retrospectively analyzed data of 173 patients who underwent complete myositis autoantibody serology examination in a medical center in Taiwan from July 2018 to February 2020. After exclusion of patients who did not receive a final diagnosis of IIM, clinical features, serology data, concomitant diseases, treatment, presence of respiratory failure, and mortality rate of the remaining 97 patients were analyzed.
RESULTS: Of IIM patients in our cohort, 47.4% had ILD. ILD was significantly associated with subtypes of IIM, older age of onset, presence of mechanic's hand, and presence of anti-Jo-1 and anti-Ro52 antibodies. Among five IIM subtypes, overlap myositis (OM) and dermatomyositis (DM) were significantly associated with a higher prevalence rate of ILD (67.5% in OM and 53.3% in DM). Among patients with OM, the presence of anti-Jo-1 (100%), anti-PL-7 (100%), and anti-EJ antibodies (77.8%) was most significantly associated with ILD.
CONCLUSION: The latest classification of IIM, older age of onset, presence of mechanic's hand, and presence of anti-Jo-1 and anti-Ro52 antibodies were significantly associated with ILD. Among five IIM subtypes, OM and DM had higher prevalence rate of ILD. Among OM patients, the presence of anti-Jo-1, anti-EJ, and anti-PL-7 antibodies was significantly associated with ILD. The study results may help physicians to timely screen and monitor pulmonary function in high-risk groups.

Entities:  

Keywords:  Autoantibodies; Idiopathic inflammatory myopathy; Interstitial lung disease

Year:  2020        PMID: 33211209     DOI: 10.1007/s10072-020-04911-7

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  41 in total

Review 1.  Lung Diseases in Inflammatory Myopathies.

Authors:  Thomas Barba; Sabine Mainbourg; Mouhamad Nasser; Jean-Christophe Lega; Vincent Cottin
Journal:  Semin Respir Crit Care Med       Date:  2019-05-28       Impact factor: 3.119

Review 2.  Classification of myositis.

Authors:  Ingrid E Lundberg; Marianne de Visser; Victoria P Werth
Journal:  Nat Rev Rheumatol       Date:  2018-04-12       Impact factor: 20.543

3.  Assessment of Mortality in Autoimmune Myositis With and Without Associated Interstitial Lung Disease.

Authors:  Cheilonda Johnson; Iago Pinal-Fernandez; Radhika Parikh; Julie Paik; Jemima Albayda; Andrew L Mammen; Lisa Christopher-Stine; Sonye Danoff
Journal:  Lung       Date:  2016-05-11       Impact factor: 2.584

Review 4.  Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment.

Authors:  Tsuneyo Mimori; Ran Nakashima; Yuji Hosono
Journal:  Curr Rheumatol Rep       Date:  2012-06       Impact factor: 4.592

Review 5.  Interstitial lung disease in inflammatory myopathies: clinical phenotypes and prognosis.

Authors:  Patrick D W Kiely; Felix Chua
Journal:  Curr Rheumatol Rep       Date:  2013-09       Impact factor: 4.592

6.  Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment.

Authors:  Armin Schnabel; Michael Reuter; Jürgen Biederer; Christiane Richter; Wolfgang L Gross
Journal:  Semin Arthritis Rheum       Date:  2003-04       Impact factor: 5.532

Review 7.  Idiopathic inflammatory myopathies and the lung.

Authors:  Jean-Christophe Lega; Quitterie Reynaud; Alexandre Belot; Nicole Fabien; Isabelle Durieu; Vincent Cottin
Journal:  Eur Respir Rev       Date:  2015-06

Review 8.  Classification and management of adult inflammatory myopathies.

Authors:  Albert Selva-O'Callaghan; Iago Pinal-Fernandez; Ernesto Trallero-Araguás; José César Milisenda; Josep Maria Grau-Junyent; Andrew L Mammen
Journal:  Lancet Neurol       Date:  2018-09       Impact factor: 44.182

Review 9.  New Myositis Classification Criteria-What We Have Learned Since Bohan and Peter.

Authors:  Valérie Leclair; Ingrid E Lundberg
Journal:  Curr Rheumatol Rep       Date:  2018-03-17       Impact factor: 4.592

Review 10.  Current Classification and Management of Inflammatory Myopathies.

Authors:  Jens Schmidt
Journal:  J Neuromuscul Dis       Date:  2018
View more
  2 in total

1.  Interstitial Lung Disease in Dermatomyositis Without Myositis-Specific and Myositis-Associated Autoantibodies: Study of a Series of 72 Patients From a Single Cohort.

Authors:  Fang Chen; Jinping Wang; Puli Zhang; Yu Zuo; Lifang Ye; Guochun Wang; Xiaoming Shu
Journal:  Front Immunol       Date:  2022-05-06       Impact factor: 8.786

2.  Muscle Biopsy: A Requirement for Precision Medicine in Adult-Onset Myopathy.

Authors:  Meng-Ju Wu; Wei-An Liao; Po-Yu Lin; Yuan-Ting Sun
Journal:  J Clin Med       Date:  2022-03-13       Impact factor: 4.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.